Sorafenib, a multikinase inhibitor targeting downstream kinases from RAS including Raf-1 and B-raf within this signaling pathway was the first approved systemic treatment for advanced HCC to demonstrate an improvement in overall survival [4]. The gene discussed is BRAF; the disease is hepatocellular carcinoma.